Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature

作者：Al-Ola A. Abdallah, Aline Herlopian, Rahul Ravilla, Meghana Bansal, Sowmya Chandra-Reddy, Fade Aziz Mahmoud, Shirley Ong, Murat Gökden, Laura Fulper Hutchins · 发表于：Journal of Oncology Pharmacy Practice · 年份：2015 · DOI：10.1177/1078155215572932 · 被引用次数：43 · 研究领域：Polyomavirus and related diseases、Cancer Immunotherapy and Biomarkers、Melanoma and MAPK Pathways

Ipilimumab is a novel humanized monoclonal antibody directed against cytotoxic T lymphocyte antigen 4, a T-cell surface molecule involved in down-regulation and suppression of the T cell response to stimuli. Patients treated with ipilimumab are at risk for immune-related adverse events involving the skin, digestive tract, liver and endocrine organs. Few case reports of immune-related adverse effects involving central or peripheral nervous system due to ipilimumab are published. These include inflammatory myopathy, aseptic meningitis, severe meningo-radiculo-neuritis, temporal arteritis, Guillain-Barre syndrome, and posterior reversible encephalopathy syndrome. We report the first case of ipilimumab-induced progressive necrotic myelopathy.